

SESSION RESUMED IN FILE 'REGISTRY' AT 12:10:11 ON 11 SEP 2009  
FILE 'REGISTRY' ENTERED AT 12:10:11 ON 11 SEP 2009  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 1.92             | 2.14          |

=> d his

(FILE 'HOME' ENTERED AT 12:04:42 ON 11 SEP 2009)

FILE 'REGISTRY' ENTERED AT 12:04:53 ON 11 SEP 2009

L1 STRUCTURE UPLOADED  
L2 11 S L1 SSS SAM  
L3 STRUCTURE UPLOADED  
L4 11 S L3 SSS SAM

=>


Uploading C:\Program Files\STNEXP\Queries\10\_614362 NK1 Antagonist compound 7  
Structure\_c.str

L5 STRUCTURE UPLOADED

=> d L5

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L5 SSS SAM

SAMPLE SEARCH INITIATED 12:10:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS  
SEARCH TIME: 00.00.01

2 ANSWERS


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 146 TO 694  
PROJECTED ANSWERS: 2 TO 124

L6 2 SEA SSS SAM L5

=> d scan L6

L6 2 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 4-Quinolinecarboxamide, 8-fluoro-3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]-  
MF C25 H21 F N2 O2

Absolute stereochemistry. Rotation (-).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 2 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 4-Quinolinecarboxamide, 7-fluoro-3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]-  
MF C25 H21 F N2 O2

Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 12:04:42 ON 11 SEP 2009)

FILE 'REGISTRY' ENTERED AT 12:04:53 ON 11 SEP 2009

L1           STRUCTURE UPLOADED  
L2           11 S L1 SSS SAM  
L3           STRUCTURE UPLOADED  
L4           11 S L3 SSS SAM  
L5           STRUCTURE UPLOADED  
L6           2 S L5 SSS SAM

=> s L4 SSS FULL

FULL SEARCH INITIATED 12:11:29 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED -       357 TO ITERATE

100.0% PROCESSED       357 ITERATIONS                   169 ANSWERS  
SEARCH TIME: 00.00.01

L7           169 SEA SSS FUL L3

=> file hcaplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 188.28           | 188.50        |

FILE 'HCAPLUS' ENTERED AT 12:11:36 ON 11 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Sep 2009 VOL 151 ISS 12

FILE LAST UPDATED: 10 Sep 2009 (20090910/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate

substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> d his

(FILE 'HOME' ENTERED AT 12:04:42 ON 11 SEP 2009)

FILE 'REGISTRY' ENTERED AT 12:04:53 ON 11 SEP 2009

L1           STRUCTURE UPLOADED  
L2           11 S L1 SSS SAM  
L3           STRUCTURE UPLOADED  
L4           11 S L3 SSS SAM  
L5           STRUCTURE UPLOADED  
L6           2 S L5 SSS SAM  
L7           169 S L4 SSS FULL

FILE 'HCAPLUS' ENTERED AT 12:11:36 ON 11 SEP 2009

=> s L7

L8           92 L7

=> s L8 and (COPD or (chronic(W)obstructive(W)pulmonary(W)disease) or emphysema or asthma)

          4998 COPD  
          268397 CHRONIC  
          17845 OBSTRUCTIVE  
          112589 PULMONARY  
          1182405 DISEASE  
          9994 CHRONIC (W) OBSTRUCTIVE (W) PULMONARY (W) DISEASE  
          5032 EMPHYSEMA  
          45510 ASTHMA  
L9           16 L8 AND (COPD OR (CHRONIC (W) OBSTRUCTIVE (W) PULMONARY (W) DISEASE)  
              OR EMPHYSEMA OR ASTHMA)

=> s L9 NOT pd>20040610

          6852770 PD>20040610

              (PD>20040610)

L10           0 L9 NOT PD>20040610

=> s L9 and (inhalable or respirable)

          1368 INHALABLE

          4447 RESPIRABLE

L11           1 L9 AND (INHALABLE OR RESPIRABLE)

=> d L11 TI AB IBIB

L11   ANSWER 1 OF 1   HCAPLUS   COPYRIGHT 2009 ACS on STN

TI   Pharmaceutical compositions for the treatment of respiratory and gastrointestinal disorders

AB   The present invention relates to novel pharmaceutical compns. comprising at least 1 EGFR kinase inhibitor and at least one addnl. active compd. selected from .beta.-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists and endothelin-antagonists, processes for prepg. the compns. and the use thereof as drugs in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes. Thus, an inhalable

powder contained an EGFR kinase inhibitor 150, formoterol fumarate dihydrate 50, and lactose 12,300 mg/capsule.

ACCESSION NUMBER: 2006:149262 HCAPLUS

DOCUMENT NUMBER: 144:239931

TITLE: Pharmaceutical compositions for the treatment of respiratory and gastrointestinal disorders

INVENTOR(S): Jung, Birgit; Himmelsbach, Frank

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG

SOURCE: PCT Int. Appl., 321 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE        |
|------------------------|--|----------|-----------------|-------------|
| WO 2006015775          | A2   | 20060216 | WO 2005-EP8385  | 20050803    |
| WO 2006015775          | A3   | 20070518 |                 |             |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |             |
| RW:                    | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA   |          |                 |             |
| US 20060035893         | A1   | 20060216 | US 2005-189643  | 20050726    |
| CA 2575541             | A1   | 20060216 | CA 2005-2575541 | 20050803    |
| EP 1784224             | A2   | 20070516 | EP 2005-773706  | 20050803    |
| R:                     | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU   |          |                 |             |
| JP 2008509177          | T  | 20080327 | JP 2007-525227  | 20050803    |
| US 20090017036         | A1   | 20090115 | US 2008-202784  | 20080902    |
| PRIORITY APPLN. INFO.: |  |          | EP 2004-18808   | A 20040807  |
|                        |  |          | US 2005-189643  | A1 20050726 |
|                        |  |          | WO 2005-EP8385  | W 20050803  |
| OTHER SOURCE(S):       | MARPAT 144:239931  |          |                 |             |

=> d his

(FILE 'HOME' ENTERED AT 12:04:42 ON 11 SEP 2009)

FILE 'REGISTRY' ENTERED AT 12:04:53 ON 11 SEP 2009

L1 STRUCTURE UPLOADED

L2 11 S L1 SSS SAM

L3 STRUCTURE UPLOADED

L4 11 S L3 SSS SAM

L5 STRUCTURE UPLOADED

L6 2 S L5 SSS SAM

L7 169 S L4 SSS FULL

FILE 'HCAPLUS' ENTERED AT 12:11:36 ON 11 SEP 2009

L8 92 S L7

L9 16 S L8 AND (COPD OR (CHRONIC(W)OBSTRUCTIVE(W)PULMONARY(W)DISEASE)  
L10 0 S L9 NOT PD>20040610  
L11 1 S L9 AND (INHALABLE OR RESPIRABLE)

=> s L9 and (anticholinergic or muscarinic)  
5611 ANTICHOLINERGIC  
28091 MUSCARINIC  
L12 9 L9 AND (ANTICHOLINERGIC OR MUSCARINIC)

=> s L12 NOT L11  
L13 9 L12 NOT L11

=> focus L13  
PROCESSING COMPLETED FOR L13  
L14 9 FOCUS L13 1-

=> d L14 1-5 TI AB

L14 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN  
TI Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes  
AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y = =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl, Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F, Cl, alkynyl, R16, OR16, SO0-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached = (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)satd. monocyclic or fused polycyclic ring; D = (un)substituted carboxy, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepd. as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of 1-hydroxybenzotriazole.bul.H2O and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide.bul.HCl in DMF/CH2Cl2 to give the pyridinecarboxamide II (R = Me) in 38% yield. Sapon. using aq. LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addn., I may be used in combination therapy with a wide variety of other therapeutic agents.

L14 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN  
TI Genetic markers in tachykinin NK1 receptor gene TACR1 that correlate with asthma disorders  
AB Polymorphisms in the exon 2 LD block of gene TACR1 encoding tachykinin receptor 1 are shown by assocn. anal. to be a susceptibility gene for asthma. Methods of diagnosis of susceptibility to asthma , of decreased susceptibility to asthma and protection against asthma, are described, as are methods of treatment for asthma.

L14 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Synthesis of 3H-pyrrolo[2,3-d]pyrimidine derivatives and use as phosphodiesterase VII inhibitors and in combination with other agents  
AB The invention concerns the synthesis of 3H-pyrrolo[2,3-d]pyrimidine derivs., their physiol. acceptable salts, stereoisomers, solvates, mixts. thereof and their use as phosphodiesterase VII inhibitors in the treatment of diseases that are influenced by the phosphodiesterase VII regulation of human eosinophil activation and degranulation. Osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, AIDS, autoimmune and heart diseases can be treated with the drugs. Thus the synthesis of 5-isopropyl-4-oxo-7-p-tolyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid Et ester and analog compds. is described along with injection, suppository, tablet and other formulations.

L14 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of indole compounds having CRTH2 antagonist activity for treating allergic diseases, asthma, and inflammatory conditions  
AB Compds. of general formula I (wherein R is Ph optionally substituted with one or more halo substituents) and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are antagonists at the CRTH2 receptor and are useful in the treatment of conditions mediated by PGD2 or other agonists binding to CRTH2. These include allergic diseases, asthmatic conditions and inflammatory diseases. A process for prep. I was addnl. claimed. Example compd. II was prep. by reacting 2-(phenylsulfonyl)benzaldehyde with 2-(5-fluoro-2-methyl-1H-indol-1-yl)acetic acid and sapon. of the resulting ester. In an assay measuring inhibition of 13,14-dihydro-15-keto-prostaglandin D2 induced blood eosinophilia in rats, II had an ED50 of 0.0025 .mu.g/mL.

L14 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Pharmaceutical compositions comprising novel anticholinergic agents and NK1-receptor antagonists for the treatment of respiratory tract diseases  
AB The invention relates to novel pharmaceutical compns. comprising novel anticholinergic agents and NK1-receptor antagonists, method for prodn. and use thereof in the treatment of respiratory diseases. Thus an inhalation capsule contained (microgram/capsule): 2,2-Diphenylpropionic acid scopolamine ester methobromide 200; N-[2-(3,5-Bis-trifluoromethylphenyl)-ethyl]-2-{4-[(3-hydroxypropyl)methylamino]piperidin-1-yl}-N-methyl-2-phenylacetamide 150; lactose 12150.

=> d L14 6-9 TI AB

L14 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Type 4 phosphodiesterase inhibitors and therapeutic uses thereof  
AB The invention discloses the use of type 4 phosphodiesterase inhibitors (PDE IV inhibitors) to treat diseases, as well as combinations of PDE IV inhibitors with other drugs.

L14 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of pyridazinyloximes as phosphodiesterase IV inhibitors.  
AB Title compds. [I; R1, R2 = H, OH, OR8, SR8, SOR8, SO2R8, halo; R1R2 = OCH2O, OCH2CH2O; R3 = H, AR7, COAR7, CO2AR7, CONH2, NH2, etc.; R7 = H, CO2H, NH2, OH, etc.; R8 = (substituted) alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, etc.; A = null, (O, S, SO, SO2, imino-interrupted) alkylene, alkenylene, cycloalkylene; B = (substituted) aryl, heteroaryl; X = (O, S, SO, SO2, imino-interrupted) alkylene], were prep. as phosphodiesterase IV inhibitors for treating osteoporosis, tumors,

cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS (no data). Thus, 3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazine was treated sequentially with chloroacetyl chloride, N-hydroxyphthalimide, ethanolamine, and 4-methoxybenzaldehyde to give 4-methoxybenzaldehyde O-[2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl]oxime.

L14 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of pyridazinylmethanoylphenylhydrazonomalonitriles as phosphodiesterase IV inhibitors.

AB Title compds. [I; R1, R2 = H, OH, OR5, SR5, SOR5, SO2R5, X; R1R2 = OCH2O, OCH2CH2O; R3, R31 = H, R5, OH, OR5, NH2, NHR5, NHCOR5, X, CO2H, CO2R5, CONH2, etc.; R4 = cyano, tetrazolyl; R5 = (fluoro-substituted) A, cycloalkyl, (CH2)nAr; A = (fluoro- and/or chloro-substituted) alkyl, alkenyl; Ar = Ph; n = 0-2; X = F, Cl, Br, iodo], were prepd. Thus, [3-(3,4-diethoxyphenyl)-5,6-dihydro-4H-pyridazine-1-yl]-(3-aminophenyl)methanone (prepn. given) was stirred with NaNO2 in aq. HCl for 1 h at -2.degree. to 0.degree.; malononitrile in H2O was added followed by stirring for 2 h to give a residue which was treated with KOH in MeOH to give 2-[[3-[1-[3-(3,4-diethoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]methanoyl]phenyl]hydrazono]malononitrile K salt. I were said to give a marked redn. of T cell proliferation. I are claimed for treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases, AIDS, etc.

L14 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes

AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R9, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; W = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepd. (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. Aq. NaOH was added to the suspension, and the reaction mixt. was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.

=> d L14 1,5 TI AB IBIB

L14 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes

AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y = =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl,

Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F, Cl, alkynyl, R16, OR16, SO0-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached = (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)satd. monocyclic or fused polycyclic ring; D = (un)substituted carboxy, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepd. as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of 1-hydroxybenzotriazole.bul.H2O and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide.bul.HCl in DMF/CH2Cl2 to give the pyridinecarboxamide II (R = Me) in 38% yield. Sapon. using aq. LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addn., I may be used in combination therapy with a wide variety of other therapeutic agents.

ACCESSION NUMBER: 2002:594842 HCAPLUS  
DOCUMENT NUMBER: 137:154859  
TITLE: Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes  
INVENTOR(S): Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony  
PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
SOURCE: PCT Int. Appl., 285 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2002060896   | A1   | 20020808 | WO 2001-IB2726  | 20011224 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW |      |          |                 |          |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
| CA 2436544  | A1   | 20020808 | CA 2001-2436544 | 20011224 |
| AU 2002222428   | A1   | 20020812 | AU 2002-222428  | 20011224 |
| EE 200300361  | A    | 20031215 | EE 2003-361     | 20011224 |
| HU 2003002891   | A2   | 20031229 | HU 2003-2891    | 20011224 |
| EP 1373258  | A1   | 20040102 | EP 2001-273558  | 20011224 |
| EP 1373258  | B1   | 20050928 |                 |          |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR   |      |          |                 |          |
| BR 2001016845   | A    | 20040225 | BR 2001-16845   | 20011224 |
| JP 2004518689   | T    | 20040624 | JP 2002-561464  | 20011224 |
| CN 1527830  | A    | 20040908 | CN 2001-823098  | 20011224 |
| NZ 526531   | A    | 20050225 | NZ 2001-526531  | 20011224 |
| AT 305467   | T    | 20051015 | AT 2001-273558  | 20011224 |
| ES 2248231  | T3   | 20060316 | ES 2001-273558  | 20011224 |

|                |    |          |                |          |
|----------------|----|----------|----------------|----------|
| US 20030027845 | A1 | 20030206 | US 2002-66503  | 20020131 |
| US 6828333     | B2 | 20041207 |                |          |
| IN 2003MN00626 | A  | 20050211 | IN 2003-MN626  | 20030620 |
| ZA 2003004893  | A  | 20040624 | ZA 2003-4893   | 20030624 |
| BG 107960      | A  | 20041029 | BG 2003-107960 | 20030701 |
| NO 2003003399  | A  | 20030925 | NO 2003-3399   | 20030730 |
| MX 2003006885  | A  | 20031113 | MX 2003-6885   | 20030730 |
| US 20050049258 | A1 | 20050303 | US 2004-918820 | 20040813 |
| US 7183293     | B2 | 20070227 |                |          |
| US 20070161681 | A1 | 20070712 | US 2007-668915 | 20070130 |

PRIORITY APPLN. INFO.:

|                 |    |          |
|-----------------|----|----------|
| US 2001-265304P | P  | 20010131 |
| WO 2001-IB2726  | W  | 20011224 |
| US 2002-66503   | A3 | 20020131 |
| US 2004-918820  | A3 | 20040813 |

OTHER SOURCE(S): MARPAT 137:154859  
 OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)  
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L14 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN  
 TI Pharmaceutical compositions comprising novel anticholinergic agents and NK1-receptor antagonists for the treatment of respiratory tract diseases  
 AB The invention relates to novel pharmaceutical compns. comprising novel anticholinergic agents and NK1-receptor antagonists, method for prodn. and use thereof in the treatment of respiratory diseases. Thus an inhalation capsule contained (microgram/capsule): 2,2-Diphenylpropionic acid scoline ester methobromide 200;  
 N-[2-(3,5-Bis-trifluoromethylphenyl)-ethyl]-2-{4-[(3-hydroxypropyl)methylamino]piperidin-1-yl}-N-methyl-2-phenylacetamide 150;  
 lactose 12150.

ACCESSION NUMBER: 2004:41273 HCAPLUS  
 DOCUMENT NUMBER: 140:99643  
 TITLE: Pharmaceutical compositions comprising novel anticholinergic agents and NK1-receptor antagonists for the treatment of respiratory tract diseases  
 INVENTOR(S): Pairet, Michel; Meade, Christopher John Montague; Pieper, Michael P.  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany  
 SOURCE: PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|--|------|----------|-----------------|----------|
| -----  | ---- | -----    | -----           | -----    |
| WO 2004004724  | A1   | 20040115 | WO 2003-EP6667  | 20030625 |
| W:   |      |          |                 |          |
| AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW:  |      |          |                 |          |
| GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  |      |          |                 |          |


BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 DE 10230750 A1 20040122 DE 2002-10230750 20020709  
 CA 2491451 A1 20040115 CA 2003-2491451 20030625  
 AU 2003242754 A1 20040123 AU 2003-242754 20030625  
 EP 1521580 A1 20050413 EP 2003-762508 20030625  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2005532378 T 20051027 JP 2004-518565 20030625  
 US 20040048886 A1 20040311 US 2003-614362 20030707  
 PRIORITY APPLN. INFO.: DE 2002-10230750 A 20020709  
 US 2002-407758P P 20020903  
 WO 2003-EP6667 W 20030625  
 OTHER SOURCE(S): MARPAT 140:99643  
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d que  
 L3 STR



Structure attributes must be viewed using STN Express query preparation.  
 L7 169 SEA FILE=REGISTRY SSS FUL L3  
 L8 92 SEA FILE=HCAPLUS ABB=ON L7  
 L9 16 SEA FILE=HCAPLUS ABB=ON L8 AND (COPD OR (CHRONIC(W)OBSTRUCTIVE  
 (W)PULMONARY(W)DISEASE) OR EMPHYSEMA OR ASTHMA)  
 L11 1 SEA FILE=HCAPLUS ABB=ON L9 AND (INHALABLE OR RESPIRABLE)  
 L12 9 SEA FILE=HCAPLUS ABB=ON L9 AND (ANTICHOLINERGIC OR MUSCARINIC)  
 L13 9 SEA FILE=HCAPLUS ABB=ON L12 NOT L11  
 L14 9 FOC L13 1-

=> d que L9  
 L3 STR



Structure attributes must be viewed using STN Express query preparation.

L7 169 SEA FILE=REGISTRY SSS FUL L3

L8 92 SEA FILE=HCAPLUS ABB=ON L7

L9 16 SEA FILE=HCAPLUS ABB=ON L8 AND (COPD OR (CHRONIC(W)OBSTRUCTIVE  
(W)PULMONARY(W)DISEASE) OR EMPHYSEMA OR ASTHMA)